News | May 18, 2025
Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
The FDA issued Form 483 with one observation related to building and facility management
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
The inspections concluded with no Form 483 observations or significant critical findings
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Cipla has received 8 inspectional observations in Form 483
Subscribe To Our Newsletter & Stay Updated
